The critical role of Hsp90 in the maintenance of several oncogenic drivers, represents an additional rationale for the use of Hsp90 inhibitors to eradicate cancer cells that have developed resistance to other targeted therapies. This evidence concerns the gene HSP90AB1 and cancer.